Pseudobulbar affect is a significant national health issue in the United States, with approximately 2 million individuals affected.
Investigators evaluated cognition with measures reflecting executive function, episodic memory, semantic fluency, and processing speed on an annual basis.
There is a positive association between residential levels of air pollution and being diagnosed with dementia.
Age, sex and apolipoprotein E genotype can identify groups at high 10-year risk for Alzheimer disease and all dementia.
Multiple pathways account for the age-related increases in dementia risk.
The burden of Alzheimer disease and related dementias is expected to increase to 3.3% in the United States by 2060.
Retinal microvascular abnormalities are identified in cognitively healthy individuals who have biomarkers positive for Alzheimer disease.
Patients with a higher mean systolic blood pressure during follow-up had increased odds for brain infarcts compared with those with lower levels.
Having high insulin at baseline was associated with a greater risk for incident diabetes mellitus compared with low insulin values.
For older adults, increased numbers of optimal cardiovascular health metrics are associated with reduced risk of dementia.
Administering the Visual Association Test improves the predictive value of the Mini-Mental State Examination score for dementia.
Abstinence in midlife and consumption of more than 14 units of alcohol per week are associated with increased risk of dementia.
Tau was found to be a significant predictor of mean diffusivity in the anterior temporal white matter.
There are currently no treatments available for frontotemporal dementia.
Positron emission tomographic imaging can directly measure synaptic loss with Alzheimer disease.
The findings suggest that confabulations by patients with AD are related to an impaired ability to mentally go back in time to retrieve the context in which the confabulated memories were encoded.
Lower cognitive ability total and verbal ability scores were predictive of greater risk for early-onset dementia.
Currently, there are no approved treatments for behavioral symptoms in Alzheimer disease.
Investigators reviewed data from patients aged 45 to 64 years who were enrolled in the Atherosclerosis Risk in Communities Study and who attended additional visits for cognitive function evaluation and repeat cardiovascular risk factor assessment.
An international team of investigators assessed the ability of flutemetamol F 18-labeled PET and other biomarkers to predict risk of clinical progression from amnestic mild cognitive impairment to probable Alzheimer disease.
Investigators sought to assess factors contributing to progression of functional, cognitive, and motor impairment in Huntington disease.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL